Biotech Values

[acgood]

I understand that the restrictions were listed as CV issues. The increased risk of neoplasia was cited as why their partner (Roche??) dropped Entereg.

I don't know the history of the product going back that far. It was partnered with GSK to sell for POI, and I think GSK had been the partner before when the development for OIC was abandoned.